header
Image from OpenLibrary

A retrospective study evaluating the patterns of molecular response to imatinib mesylate in Egyptian patients with chronic myeloid leukemia in respect to pretreatment BCR-ABL transcripts level / Yasser Ibrahim Hassan Elnahass ; Supervised Mervat Mohamed Mattar , Mohammed Abdelmooti Samra , Hala Mahmoud Abdelhamid

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Yasser Ibrahim Hassan Elnahass , 2013Description: 110P. : charts , facsimiles; 25cmOther title:
  • دراسة استعادية لتقييم العلاقة بين الاستجابة الجزيئية لمرضى اللوكيميا الميلودية المزمنة لعقار ايماتينيب ميثيلات والمستوى الكمى لجين البيسى ار - ابل قبل العلاج [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Internal Medicine Summary: CML is a clonal myeloproliferative neoplasm characterized by specific translocation t (9;22) (q34;q11) The novel chimeric protein BCR-ABL dictates the pathophysiology of the disease . The first TKI approved by the US FDA for treatment of ph +CP - CML was imatinib masylate (IM) . Newer TKIs nilotinib and dasatinib have been commercially available for more than 5 years and were indicated for patients who developed resistance or intolernce to IM . In 2010 both drugs became FDA approved as 1s line therapy in CP - CML
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.18.M.Sc.2013.Ya.R (Browse shelf(Opens below)) Not for loan 01010110060620000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.18.M.Sc.2013.Ya.R (Browse shelf(Opens below)) 60620.CD Not for loan 01020110060620000

Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Internal Medicine

CML is a clonal myeloproliferative neoplasm characterized by specific translocation t (9;22) (q34;q11) The novel chimeric protein BCR-ABL dictates the pathophysiology of the disease . The first TKI approved by the US FDA for treatment of ph +CP - CML was imatinib masylate (IM) . Newer TKIs nilotinib and dasatinib have been commercially available for more than 5 years and were indicated for patients who developed resistance or intolernce to IM . In 2010 both drugs became FDA approved as 1s line therapy in CP - CML

Issued also as CD

There are no comments on this title.

to post a comment.